BMC Pharmacology and Toxicology, 2020 Background The purpose of this study was to evaluate and compare the effects on laboratory parameters among monotherapy with five DPP-4 inhibitors in patients with type 2 diabetes mellitus (DM). Methods We identified cohorts of new sitagliptin users (n =
Yayoi Nishida +5 more
doaj +1 more source
Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013. [PDF]
, 2016 ObjectiveTo examine temporal trends in utilization of glucose-lowering medications, glycemic control, and rate of severe hypoglycemia among patients with type 2 diabetes (T2DM).Research design and methodsUsing claims data from 1.66 million privately ...
Gill, Thomas M +9 more
core +1 more source
Function of Bmpr1a in ES cell differentiation and cell competition [PDF]
, 2010 Bone morphogenetic protein (BMP) 4 signalling via BMPR1A is required for the maintenance of the epiblast in the early embryo, and for self-renewal of pluripotent mouse embryonic stem (ES) cells by inhibiting neural differentiation.
Sancho, Maria Margarida Gouveia +1 more
core +1 more source
DPP-4 Inhibitor–Related Pancreatitis: Rare but Real! [PDF]
Diabetes Care, 2017 Following the U.S. Food and Drug Administration (FDA) Guidance issued in 2008 to demonstrate cardiovascular safety for the purpose of regulatory approval of new glucose-lowering agents for type 2 diabetes management, the number of placebo-controlled randomized clinical trials has increased exponentially.
DeVries, J. Hans, Rosenstock, Julio
openaire +2 more sources
In Silico approaches applied to the study of peptide analogs of ile-pro-ile in relation to their dipeptidyl peptidase IV inhibitory properties [PDF]
, 2018 peer-reviewedInhibition of dipeptidyl peptidase IV (DPP-IV) may be exploited to maintain the incretin effect during the postprandial phase. As a result, glycemic regulation and energy homeostasis may be improved. Food protein-derived peptides have been
Cozzini, Pietro +5 more
core +3 more sources
Journal of Diabetes Investigation, 2019 Aims/Introduction The objective of the present study was to elucidate the effect of switching to teneligliptin from other dipeptidyl peptidase‐4 (DPP‐4) inhibitors on glucose control and renoprotection in type 2 diabetes mellitus patients with diabetic ...
Munehiro Kitada +8 more
doaj +1 more source
Az entero-inzularis tengely (dipeptidyl peptidase-4-incretin rendszer) jelentősége diabetesben és különböző kóros glükóztoleranciával járó állapotokban = Significance of the entero-insular axis (dipeptidyl peptidase-4–incretin system) in diabetes and in various conditions with impaired glucose tolerance [PDF]
, 2011 • Az éhomi szérum DPP-4 aktivitás nem magasabb 2-es típusú cukorbetegekben (T2DM), ha –klinikailag a nem alkoholos zsírmájbetegséget (NAFLD) a csoportból kizárjuk.
Firneisz, Gábor
core
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease [PDF]
, 2009 Classical non-insulin antihyperglycemic drugs currently approved for the treatment of type 2 diabetes mellitus (T2DM) comprise five groups: biguanides, sulfonylureas, meglitinides, glitazones and alpha-glucosidase inhibitors.
Enrique Z Fisman, Alexander Tenenbaum
core +1 more source
Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [PDF]
, 2016 This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source.
Al-Tawfiq, Jaffar A., Memish, Ziad A.
core +1 more source